Back to Search
Start Over
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.
- Source :
-
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2021 Feb; Vol. 51 (2), pp. 286-292. - Publication Year :
- 2021
-
Abstract
- Coagulopathy represents one of the most important determinants of morbidity and mortality in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or higher doses are needed, especially in severe patients, is unknown. To evaluate the safety of intermediate dose regimens of low-weight molecular heparin (LWMH) in COVID-19 patients with pneumonia, particularly in older patients. We retrospectively evaluated 105 hospitalized patients (61 M, 44 F; mean age 73.7 years) treated with subcutaneous enoxaparin: 80 mg/day in normal weight and mild-to-moderate impair or normal renal function; 40 mg/day in severe chronic renal failure or low bodyweight (< 45 kg); 100 mg/day if bodyweight was higher than 100 kg. All the patients had radiologically confirmed pneumonia and 63.8% had severe COVID-19. None of the patients had fatal haemorrhage; two (1.9%) patients had a major bleeding event (one spontaneous hematoma and one gastrointestinal bleeding). Only 6.7% of patients needed transfusions of red blood cells. One thrombotic event (pulmonary embolism) was observed. When compared to younger patients, patients older than 85 years had a higher mortality (40% vs 13.3%), but not an increased risk of bleeding or need for blood transfusion. The use of an intermediate dose of LWMH appears to be feasible and data suggest safety in COVID-19 patients, although further studies are needed.
- Subjects :
- Aged
Aged, 80 and over
COVID-19 etiology
COVID-19 mortality
Enoxaparin adverse effects
Female
Follow-Up Studies
Humans
Italy epidemiology
Kidney Failure, Chronic complications
Kidney Failure, Chronic drug therapy
Male
Middle Aged
Retrospective Studies
Thrombosis etiology
Enoxaparin administration & dosage
SARS-CoV-2
Thrombosis prevention & control
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 1573-742X
- Volume :
- 51
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of thrombosis and thrombolysis
- Publication Type :
- Academic Journal
- Accession number :
- 32794132
- Full Text :
- https://doi.org/10.1007/s11239-020-02243-z